Source: Breathe, 16 (4) 200224; 10.1183/20734735.0224-2020
Disease area: Respiratory critical care



Rating:

Share or cite this content

Citations should be made in the following way:
Rebecca F. D'Cruz, Nicholas Hart, Georgios Kaltsakas. High-flow therapy: physiological effects and clinical applications. Breathe, 16 (4) 200224; 10.1183/20734735.0224-2020

Member's Comments

No comment yet.

Related content which might interest you: Update on novel anticoagulants: indications, dosing alternatives and outcomes Source: International Congress 2018 – Pulmonary embolism: what we need to know Year: 2018 Assessing the effect of medical therapy in COPD: from pathophysiology and biomarkers to clinical practice Source: Annual Congress 2009 - PG15 The complexity of COPD: assessment and advanced therapies Year: 2009 Clinical implications and novel therapies Source: International Congress 2018 – Accelerated ageing in lungs Year: 2018 Bronchodiator therapy in COPD: physiological effects Source: Breathe 2008; 4: 342-344 Year: 2008 COPD mechanisms: novel aspects and implications for new therapies Source: ERS Live 2007 Year: 2007 COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness Source: Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020 Year: 2020 Comparative efficacy of the therapy strategies for the asthma control maintenance in real clinical practice Source: Annual Congress 2011 - Asthma: control and treatment Year: 2011 Clinical implications and opportunities for new drug therapies Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications Year: 2008 A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials Source: Eur Respir J 2015; 46: 243-249 Year: 2015 COVID-19 vaccines: immunology, regulation and clinical management Source: Eur Respir Monogr 2021; 94: 244-260 Year: 2021 At the interface: the translational science supporting the clinical use of anti-cytokine therapy Source: International Congress 2018 – New biologics for asthma: which patients, which agents, which results, at what cost? Year: 2018 Our experience of 200 patients: Usage and maintenance of long-term oxygen therapy and non-invasive ventilation devices at home Source: Annual Congress 2013 –Long-term NIV: COPD, sleep, obesity and outcomes Year: 2013 Biologics: current use and future applications for personalised therapy Source: Virtual Congress 2021 – Wheezing illnesses along the life span Year: 2021 Novel paradigm for inhaled therapies: simulation of drug pharmacokinetic behaviour and effect of disease Source: Eur Respir J 2003; 22: Suppl. 45, 474s Year: 2003